DXCM Stock Recent News
DXCM LATEST HEADLINES
Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities in the U.S. The post Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried appeared first on Investor's Business Daily.
It might be tempting to pull your money out of the S&P 500 given President Trump's trade-war mongering. The post Analysts Say 6 Rising Stocks Are Your Best Bets Amid Trump appeared first on Investor's Business Daily.
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down nearly 7% after the bell.
DexCom, Inc. (NASDAQ:DXCM ) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of Investor Relations Conference Call Participants Jayson Bedford - Raymond James Jayson Bedford Good morning. Welcome to the 46th Annual Raymond James Institutional Investors Conference.
The best way to grow your wealth and better prepare yourself for retirement is to accumulate shares of solid growth stocks to own for the long term. As these companies steadily grow their revenue and profits, they become more valuable, and investors will be willing to pay more for them.
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns.
Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster strength but suggest investors bring an "umbrella' to protect their portfolios.
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.